There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

A new international multicenter study published in the Journal of Cellular and Molecular Medicine provides important real-world evidence on the use of CD19-targeted chimeric antigen receptor (CAR) ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

CAR-T therapy was originally developed for leukemias and lymphomas, and the breakthrough treatment is now also being used for ...

Early CAR T cell expansion is associated with both therapeutic activity and inflammatory toxicity, such as cytokine release syndrome and neurotoxicity. Routine flow cytometry can reliably track ...

Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...

Lyell Immunopharma has acquired exclusive worldwide rights from Innovative Cellular Therapeutics (ICT) to LYL273, an advanced ...

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

In a licensing deal unveiled Monday, Lyell Immunopharma is handing over $40 million in cash and almost 2 million of its ...

A new systematic review shows CAR T-cell therapy delivers high remission rates, reduced disease activity, and low toxicity in ...

India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence ...